Pfizer Declares First-Quarter 2019 Dividend
Board of Directors approves increase in quarterly cash dividend to $0.36 per share and authorizes
new $10 billion share repurchase program
The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock,
payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by
approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st
consecutive quarterly dividend paid by Pfizer.
Keeping with past practice, the board of directors also authorized a new $10 billion share repurchase program to be utilized
over time. This new program is in addition to the $4.9 billion remaining under the company’s current authorization.
“We are confident in the business and focused on maximizing total shareholder return, of which the dividend remains a key
component,” stated Ian Read, Pfizer chairman and chief executive officer.
About Pfizer: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference
for all who rely on us. We routinely post information that may be important to investors on our website at
www.pfizer.com. In addition, to learn more, please visit us on
www.pfizer.com or follow us on Twitter at
@Pfizer and
@Pfizer_News,
LinkedIn,
YouTube and like us on Facebook at
Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of December 14, 2018. The Company assumes no obligation to
update forward-looking statements contained in this release as a result of new information or future events or
developments.
This release contains forward-looking information about the Company’s share repurchase program, business and total
shareholder return that involves substantial risks and uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in
research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks
related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or
global capital markets, credit markets, regulatory environment or economies generally; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
Media Contact:
Patricia Kelly
(212) 733-3810
Investor Contact:
Ryan Crowe
(212) 733-8160
View source version on businesswire.com: https://www.businesswire.com/news/home/20181214005395/en/